BioSpace News Archive

Presentation of 87 Abstracts Revealing New Insights into Acute Kidney Injury, Artificial Intelligence Technology, Home Dialysis, and Other Efforts to Improve Patient Outcomes

Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, announced that the Company’s management will present its platform technology and discuss potential utility of RNAi therapeutics at two conferences in November 2019.

Supports the first round of public private cooperative agreements to develop patient-centric quality measures in cancer for CMS

First clinical data from Phase 1 study of MGTA-145 show successful mobilization of target number of stem cells in 11 of 12 healthy volunteers within hours; updated data including apheresis collection to be presented at ASH

Updated safety and efficacy results from ongoing Phase 1 CRB-402 study of bb21217 in relapsed/refractory multiple myeloma

St. Jude Children’s Research Hospital and the National Institutes of Health to present updated MB-107 clinical data for the treatment of X-linked severe combined immunodeficiency

MacroGenics, Inc. announced the clinical and preclinical abstracts related to flotetuzumab, the Company’s investigational bispecific CD123 x CD3 DART® molecule, to be presented at the 61st American Society of Hematology Annual Meeting & Exposition in Orlando, Florida, from December 7-10, 2019.

Today, LifeSciences BC, a non-profit, industry association which supports and represents the life sciences community of British Columbia, and Lumira Ventures, a leading North American healthcare venture capital firm, will host the 4th annual LifeSciences BC’s Investor Summit in Vancouver, BC.

The research conducted with this grant will extend and further enhance the company’s dental bone graft solution with the localized release of non-opioid pain medications to reduce the need for opioids prescribed in conjunction with wisdom tooth extractions. [06-November-2019] LOWELL, Mass. , Nov. 5, 2019 /PRNewswire/ -- LaunchPad Medical, Inc. announced that it has re

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that the company will be hosting an Event at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2019 in Orlando, FL.